New drug ARO-HSD aims to tame fatty liver disease in early trial
NCT ID NCT04202354
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This study tested an experimental drug called ARO-HSD in 50 people, including healthy volunteers and patients with NASH (a serious fatty liver disease). The main goal was to check safety and how the drug moves through the body. Researchers gave single or multiple doses to see if it could help control the disease, but this is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Auckland Clinical Studies
Grafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.